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internalization of the uPA:serpin complexes
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When active uPA or the pro-enzyme pro-uPA are bound
The GPI-anchored urokinase plasminogen activator to uPAR, they are not internalized and remain on the cell
receptor (uPAR) does not internalize free urokinase surface (Vassalli et al., 1985; Stoppelli et al., 1985,
(uPA) but readily internalizes and degrades uPA:serpin 1986; Cubellis et al., 1986). When receptor-bound uPA is
complexes in a process that requires the α2-macro- complexed to the specific plasminogen activator inhibitor
globulin receptor/low density lipoprotein receptor- type 1 (PAI-1) or to protease nexin-1 (PN-1), the complex
related protein (α2MR-LRP). This process is accom- is internalized and degraded in the lysosomes (Cubellis
panied by the internalization of uPAR which renders et al., 1990; Estreicher et al., 1990; Jensen et al., 1990;
it resistant to phosphatidylinositol-specific phospholip- Conese et al., 1994). Binding to uPAR is required for
ase C (PI-PLC). In this paper we show that during internalization and degradation of the uPA:PAI-1 and
internalization of uPA:serpins at 37°C, analysed by uPA:PN-1 complexes (Olson et al., 1992; Conese et al.,
FACScan, immunofluorescence and immunoelectron 1994) and internalization and degradation of the uPA:
microscopy, an initial decrease of cell surface uPAR serpin complexes requires a trans-membrane partner which
was observed, followed by its reappearance at later has been identified as a member of the LDL-receptor
times. This effect was not due to redistribution of family: the α2-macroglobulin receptor/low density lipo-
previously intracellular receptors, nor to the surface protein receptor-related protein (α2MR-LRP), the epithe-
expression of newly synthesized uPAR. Recycling was lial glycoprotein-330 or the VLDL-receptor (Herz et al.,
directly demonstrated in cell surface-biotinylated, uPA: 1992; Nykjær et al., 1992; Moestrup et al., 1993; Conese
PAI-1-exposed cells in which biotinylated uPAR was et al., 1994; Argraves et al., 1995; Heegaard et al., 1995).
first internalized and subsequently recycled back to The endocytic α2MR-LRP is expressed by several cultured
the surface upon incubation at 37°C. In fact, uPAR cells (Moestrup et al., 1992), and binds a variety of
was resistant to PI-PLC after the 4°C binding of ligands, including α2-macroglobulin:proteinase (Moestrup
uPA:PAI-1 to biotinylated cells, but upon incubation et al., 1990; Moestrup and Gliemann, 1991) and plasmin-
at 37°C PI-PLC-sensitive biotinylated uPAR re- ogen activator–serpin complexes (Nykjær et al., 1992;
appeared at the cell surface. Binding of uPA:PAI-1 by Orth et al., 1992; Conese et al., 1994). The 39 kDa
uPAR, while essential to initiate the whole process, Receptor Associated Protein (RAP), capable of competing
was, however, dispensable at later stages as both for binding with all ligands, the soluble α2MR-LRP and
internalization and recycling of uPAR could be anti-α2MR-LRP antibodies, inhibit uPA:serpin internaliz-
observed also after dissociation of the bound ligand ation (Nykjær et al., 1992; Conese et al., 1994). Unexpec-
from the cell surface. tedly, also uPAR is internalized in the process and also
Keywords: internalization/recycling/uPA:serpin complex/ this step is dependent on α2MR-LRP (Conese et al.,
urokinase receptor 1995). We now show that internalized uPAR can be
recycled back to the cell surface.
Results
Introduction
uPA:serpin-internalized uPAR is resistant to release
Binding of urokinase plasminogen activator (uPA) to its by PI-PLC
specific receptor (uPAR) regulates cell migration and PI-PLC releases cell surface uPAR (Ploug et al., 1991)
and hence should release the bound ligand quantitatively.invasiveness (Blasi et al., 1987, 1994; Danø et al., 1994;
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Table I. Comparison of acid-washing and PI-PLC treatment on the release of [125I]uPA, [125I]uPA:PAI-1 or [125I]uPA:rPN-1 from LB6 clone 19 cells
and T-lymphocytes
Ligand/treatment 125I-ligand released (%)
LB6 clone 19 T-lymphocytes
–  – 
uPA/AW 88.6  5.0 88.9  4.5 73  3.0 75  2.0
uPA:PAI-1/AW 82.0  1.0 85.3  2.1 92  4.0 82  8.2
uPA:rPN-1/AW 71.0  3.2 82.0  2.8 ND ND
uPA/PI-PLC 89.3  4.9 88.8  5.2 99  0.5 95  2.0
uPA:PAI-1/PI-PLC 36.0  4.3 78.0  2.0 94.0  2.3 94.0  3.0
uPA:rPN-1/PI-PLC 27.0  4.1 48.0  1.0 ND ND
LB6 clone 19 cells (0.2106/well) were incubated with [125I]uPA, [125I]uPA:PAI-1 or [125I]uPA:rPN-1 for 120 min on ice in the presence of control
GST (50 μg/ml) (–) or GST–RAP (50 μg/ml) (), then washed and treated with acid-washing (AW) or PI-PLC (see Materials and methods).
T-lymphocytes (1106/ml) were incubated with [125I]uPA or [125I]uPA:PAI-1 for 16 h at 4°C in the presence () or absence (–) of 200 nM rRAP.
The ligands were used at 6 nM concentration with a specific activity of 21–65.7106 c.p.m./μg. The amount of released ligand is expressed as
percentage of the total cell-associated radioactivity before treatments ( standard deviation). Non-specific counts were determined by competition
with 200 nM pro-uPA and subtracted. Each value is derived from one experiment in triplicate and was reproduced three times.
We incubated LB6 clone 19 cells or activated human ments (not shown). First, we noticed that the intensity of
fluorescence in uPA:PAI-1-treated LB6 clone 19 cellsprimary T-lymphocytes with radiolabelled ligands at 4°C,
and compared the releasing effect of acid-washing (which incubated at 37°C for 0–120 min did not decrease over
time, as occurred when the uPA antibody was used (notdissociates the ligand) or PI-PLC treatment (which releases
the receptor) (Stoppelli et al., 1986; Ploug et al., 1991) on shown; but see Olson et al., 1992). Figure 1 shows selected
illustrations of uPAR immunofluorescence taken at differ-cell-bound [125I]uPA, [125I]uPA:PAI-1 or [125I]uPA:PN-1.
Table I shows that ~90% of the ligand was released with ent planes of focus. The left series (a, d, g and j)
shows a look-through projection of all confocal planes,the two methods with both types of cell exposed at 4°C
to free [125I]uPA. However, in LB6 clone 19 cells when corresponding to normal epifluorescence. The centre series
(b, e, h and k) shows a single confocal plane (0.2 μm)the ligands were [125I]uPA:PAI-1 or [125I]uPA:rPN-1 com-
plexes, acid-washing released 83% and 71% of the ligands, passing through the adhesion plane. The right series (c, f,
i and l, higher magnification) is also a single confocalwhile PI-PLC released only 36% and 27%, respectively.
Treatment with PI-PLC was carried out for 15 min at section (0.2 μm) passing through the centre of the cell.
On completion of the 4°C incubation (time 0, not shown),37°C, while acid-washing was carried out entirely at 4°C.
Since internalization causes PI-PLC resistance of uPAR and after 10 min at 37°C (Figure 1), staining was concen-
trated mainly at the cell periphery. After 30 and 60(Conese et al., 1995), the results in Table I might be
explained by a uPAR-dependent internalization of the min at 37°C, most of the previously peripheral uPAR
fluorescence was redistributed to a perinuclear position,ligand occurring within the 37°C PI-PLC incubation
time (15 min). Indeed, the α2MR-LRP antagonist RAP shown previously by a variety of techniques to be caused
by uPAR internalization (Conese et al., 1995). The peri-prevented PI-PLC resistance (Table I). In agreement with
this interpretation, activated T-lymphocytes, which express nuclear location was specific for cells incubated with
uPA:serpins and exposed at 37°C, and was inhibited byuPAR but not α2MR-LRP (our unpublished results),
displayed identical [125I]uPA:PAI-1 release by PI-PLC and the ligand of α2MR-LRP, RAP (not shown; see Conese
et al., 1995). When the incubation at 37°C was prolongedby the acid treatment (Table I).
To confirm that a 15-min treatment at 37°C would to 120 min, uPAR fluorescence did not diminish but was
found to be re-concentrated at the cell periphery, at sitesbe sufficient to internalize the uPA:PAI-1 complex, we
performed a detailed time-course experiment of uPA:PAI-1 reminiscent of contacts with the plastic dish. This is better
seen Figure 1, panels c, f, i and l (high magnification). Ininternalization/degradation and confirmed that such condi-
tions were indeed sufficient to attain almost maximal conclusion, these data showed the striking absence of any
time-dependent decrease of uPAR staining over the timeinternalization of the bound uPA:PAI-1, and that this event
was suppressed by 200 nM RAP (data not shown). frame examined, suggesting that internalization of uPAR
may not be followed by its degradation. It is important toWe conclude therefore that the α2MR-LRP-dependent
internalization of uPAR occurs very rapidly at 37°C. We point out that after a 1-h incubation at 37°C, these
same cells had already degraded ~50% of uPA:PAI-1also conclude that PI-PLC treatment would not affect
internalized uPAR. (not shown).
Since internalized uPAR is PI-PLC-resistant, treatment
of cells with PI-PLC should not eliminate the immuno-Internalization of uPAR is not followed by
degradation fluorescence signal due to internalized uPAR. We used
LB6 clone 19 cells incubated for 90 min at 4°C in theLB6 clone 19 cells previously challenged at 4°C with
excess uPA:PAI-1, were incubated at 37°C for different absence of ligands, or in the presence of 10 nM uPA or
uPA:PAI-1. In both the absence and presence of ligands,times, treated with anti-uPAR antibodies, and subjected
to immunofluorescence confocal microscopy. The staining antibodies to uPAR stained the surface of non-permeabil-
ized cells homogeneously (not shown), as previouslywas highly specific, as seen in a series of control experi-
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Fig. 1. Confocal immunofluorescence microscopy analysis of uPAR in LB6 clone 19 cells challenged with uPA:PAI-1 and then incubated for 10–120
min at 37°C. Cells were incubated with uPA:PAI-1 for 2 h at 4°C, washed and then incubated at 37°C for 10 min (a–c), 30 min (d–f), 60 min (g–i)
or 120 min (j–l). Cells were then washed, permeabilized, treated with 15 μg/ml anti-uPAR R2 monoclonal antibody and developed with
fluoresceinated anti-mouse IgG. Bars: 35 μm in the panels a, d, g and j; 12 μm in panels c, f, i and l.
reported by Conese et al. (1995). After 90 min at 4°C, 1992; Conese et al., 1995). To test for uPAR recycling,
the cells were washed, treated with PI-PLC for 15 min at U937 cells were exposed to either uPA:PAI-1 or uPA:PN-1
37°C, and permeabilized. In this case, the signal observed for 90 min at 4°C, washed, further incubated at 37°C, and
varied depending on the ligand. In the absence of ligands then subjected to cytofluorimetric analysis with uPAR-
or in the presence of uPA, staining disappeared almost specific antibodies. As expected, uPA:PAI-1 and
completely (Figure 2, upper and centre panels). When the uPA:rPN-1 complexes down-regulate uPAR after 30 min
ligand was uPA:PAI-1, however, uPAR staining disap- at 37°C (Figure 3, panels A, F and B, G) and this was
peared from the cell surface and was replaced by an prevented by the α2MR-LRP antagonist, RAP (Figure 3,
intracellular punctuate pattern reminiscent of that seen panels C and H). When, however, the incubation was
with internalized proteins (Figure 2, lower panel). A similar continued for 60 or 120 min, the level of uPAR-specific
picture was obtained when the ligand was uPA:rPN-1 (not fluorescence reverted to normal and at 120 min the
shown). We conclude that PI-PLC can be employed to
FACScan signal was almost identical to that at time zero
study the steps following uPAR internalization, as the
(Figure 3, panels D, E and I, J). This result suggests
enzyme will release the surface-bound, but not the internal-
that internalized uPAR might be recycled back to theized, uPAR.
cell surface.
The events following internalization of uPAR were alsoInternalized uPAR recycles back to the cell surface
analysed by electron microscopy of cryosections preparedU937 monocyte-like cells incubated with uPA:serpin com-
plexes down-regulate their surface uPAR (Olson et al., for immunocytochemistry, using LB6 clone 19 cells incub-
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Fig. 3. Immunocytofluorimetric analysis of the surface uPAR
expression in U937 cells at different times after addition of uPA:PAI-1
or uPA:PN-1. Acid-washed cells were incubated with 10 nM
uPA:PAI-1 (A–E) or uPA:PN-1 (F–J) for 90 min at 4°C and then at
37°C for 0 (A and F), 30 min (B, C, G and H), 60 min (D and I) or
120 min (E and J). In panels C and H, the cells had received 200 nM
RAP in addition to the ligand. The presence of uPAR was analysed by
FACS analysis by the use of the anti-uPAR monoclonal antibody R2
(25 μg/ml) (see Materials and methods). Control peak (c) in panel A
refers to cells treated with fluorescein-conjugated secondary antibody
only.
Fig. 2. Immunofluorescence microscopy analysis of uPAR in PI-PLC-
treated LB6 clone 19 cells. Incubation of cells with uPA:PAI-1 induces
partial resistance to PI-PLC. Cells were incubated with no ligand,
10 nM uPA or 10 nM uPA:PAI-1 complex, for 2 h at 4°C, washed and
then incubated 15 min at 37°C with PI-PLC. The cells were then showed that uPAR could at least in part be recycled back
washed, permeabilized and subjected to epifluorescence after treatment to the plasma membrane.
with the anti-uPAR monoclonal antibody R2 (see Materials and To directly test recycling of uPAR to the cell surface,
methods).
we labelled cell surface uPAR with biotin and then
followed its fate after internalization by immunoprecipit-
ation and avidin detection. Surface-biotinylated LB6 clone
19 cells were challenged with uPAR-saturating levelsated and prepared as described in Materials and methods.
After incubation for 2 h at 0°C, with 100 nM uPA:PAI-1, (50 nM) of ATF or uPA:PAI-1 for 120 min at 4°C, washed,
incubated at 37°C for 15 min and treated with PI-PLC forchase for 15 min at 37°C, and treatment with PI-PLC
(protocol a, see Materials and methods), most of the 15 min at 37°C. The PI-PLC supernatant and the cell
lysate were immunoprecipitated with uPAR antibodies andlabelling (78%) was found over intracellular vacuoles, and
22% on the plasma membrane (Figure 4A). However, biotinylated uPAR was detected by avidin-blotting. As
shown in Figure 5A, all uPAR was detected in the PI-PLCafter chase–incubation at 37°C for 120 min (protocol b),
labelling on the plasma membrane rose to 44% and supernatant when the cells were not exposed to any ligand.
Figure 5B shows the results of PI-PLC treatment in ligand-intracellular vacuolar labelling fell to 56% (Figure 4B).
To exclude transport of newly synthesized uPAR to treated cells: when cells were exposed to ATF, uPAR was
again found in the PI-PLC supernatant; in contrast, whenthe plasma membrane, all buffers contained 10 μg/ml
cycloheximide. Thus, immunoelectron microscopy also cells were incubated with uPA:PAI-1, uPAR was found
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Fig. 4. Immunoelectron microscopic analysis of the fate of internalized uPAR. The cells were incubated as in protocol a (see Materials and methods)
(A) with 100 nM uPA:PAI-1 for 2 h at 0°C, chased for 15 min at 37°C and treated with PI-PLC or, according to protocol b (B) after a 120 min
chase at 37°C. Electron micrographs from cryosections were prepared for immunocytochemistry as described in Materials and methods. (A) Virtually
no labelling is seen on the plasma membrane (arrowheads). Intracellular vacuoles (V) are labelled. No labelling is seen over the nucleus (N).
(B) Intense labelling is seen on the plasma membrane (arrowheads). Labelling is also seen in vacuoles (V). Bars, 0.25 μm.
mostly in the cell lysate, with only a very small fraction The uPA:PAI-1 ligand, though required to initiate
the process, is not required for thereleased into the supernatant. To study recycling, the
PI-PLC-treated cells were further incubated at 37°C for internalization/recycling step
The binding of the uPA:serpin complex is required todifferent time intervals and subjected to a second PI-PLC
treatment (now 4°C for 90 min) to prevent re-internaliz- induce PI-PLC resistance (i.e. internalization) of uPAR
(Conese et al., 1995). Since ligand dissociation by acid-ation (these conditions were found efficiently to release
surface uPAR; not shown). As shown in Figure 5C, in washing does not release uPAR (Stoppelli et al., 1986),
we can test whether the continuous presence of thethe case of ATF-challenged cells, PI-PLC supernatants
contained little, if any, uPAR. Alternatively, the PI-PLC ligand is required for uPAR internalization and recycling.
Unlabelled uPA or uPA:PAI-1 complex (50 nM) wassupernatants of uPA:PAI-1-challenged cells showed minor,
though significant, uPAR after only 2 min of incubation bound to LB6 clone 19 cells for 120 min at 4°C. The
surface-bound ligand was then removed with acid and theat 37°C, and higher levels after 20–30 min of incubation.
Concomitantly, uPAR levels were strongly reduced in the washed cells treated with PI-PLC for 15 min at 37°C. The
released uPAR was assayed in the PI-PLC supernatant bycell pellet. The detection of biotinylated uPAR on the cell
surface clearly indicates that it can recycle back to [125I]ATF cross-linking, SDS–PAGE and autoradiography.
The cell pellet was collected, lysed and analysed similarly.that location.
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Fig. 6. Bound uPA:PAI-1 is not required for the maintenance of uPAR
PI-PLC resistance in LB6 clone 19 cells. LB6 clone 19 cells (0.2106
cells/well) were incubated in the absence of ligand (A), in the
presence of 50 nM uPA or of 50 nM uPA:PAI-1 (B) for 2 h at 4°C.
The cells were acid-washed in the cold to remove ligands and treated
with PI-PLC for 15 min at 37°C. Solubilized uPAR was assayed on
the PI-PLC supernatant (S) or on the lysate of the cell pellet (L) by
[125I]ATF cross-linking and SDS–PAGE analysis. In (B) the
experiment was carried out in the absence (–) or in the presence ()
of 10 μg/ml cycloheximide (see text) to block protein synthesis.
Fig. 5. Recycling of cell surface-biotinylated uPAR in uPA:PAI-1-
challenged LB6 clone 19 cells. Cells were surface-biotinylated before
treatments and uPAR was detected in the PI-PLC supernatant (S) and
could be reversed upon incubation at 37°C indicates thatcell lysate (L) by immunoprecipitation with anti-uPAR antiserum and
avidin detection. (A) In untreated cells uPAR was found exclusively in internalized uPAR can be recycled back to the cell surface,
the supernatant after release with PI-PLC. (B) In cells incubated with even after dissociation of the uPA:PAI-1 ligand.
50 nM ATF or uPA:PAI-1 for 120 min at 4°C, and then at 37°C for 15
Internalization of uPAR is also induced by uPA:serpinsmin, PI-PLC released uPAR in the supernatant only in the case of
in suspension growing monocyte-like U937 cells (ConeseATF. In the case of uPA:PAI-1 treatment, uPAR was PI-PLC-resistant
and was found in the cell lysate. (C) The cells were treated with ATF, et al., 1995). We therefore repeated the above experiment
incubated for a further 2–30 min at 37°C and then challenged again in U937 cells. The uPA-challenged U937 cells (Figure
with PI-PLC for 15 min at 37°C; they showed neither reappearance of
7C, lane 2), showed a specific [125I]ATF–uPAR adduct
uPAR in the supernatants nor a decrease in the cell lysates. (D) In
in the PI-PLC supernatant independently of the 37°CuPA:PAI-1-treated cells, uPAR did reappear on the cell surface as
shown by its release by PI-PLC in the supernatant and its decrease in incubation step. However, [125I]ATF–uPAR adduct was
the cell lysate. detected in uPA:PAI-1-challenged cells only after incuba-
tion at 37°C (Figure 7C, lane 8). Similar results were
obtained with cells challenged with uPA:PN-1 complexIn the absence of ligand, all uPAR was released by PI-PLC
(Figure 7D). This result again shows that both internaliz-(Figure 6A). In uPA:PAI-1-treated cells, the specific [125I]-
ation and recycling of uPAR can occur also in suspensionATF–uPAR conjugate was found in the cell-associated
growing cells, after dissociation of the ligand. The experi-fraction, but not in the PI-PLC supernatant (Figure 6B).
ment also shows that not only uPA:PAI-1, but alsoThe effect was specific, since in uPA-treated cells, uPAR
uPA:PN-1 complex caused uPAR internalization andwas found in the PI-PLC supernatant. Thus, although
recycling.uPA:PAI-1 was required to induce PI-PLC resistance
Reversion to PI-PLC sensitivity might also be explainedof uPAR at 4°C, its removal did not prevent uPAR
by cell surface redistribution of either an intracellular poolinternalization.
or of newly synthesized receptors. The latter possibilityIf the removal of the ligand does not prevent uPAR
seems unlikely because identical results were obtained ininternalization, it might also not prevent its recycling. To
two cell lines, where different regulatory mechanismstest this point, the two cell lines, U937 and LB6 clone
govern uPAR synthesis. In human U937 cells, ~510419, were treated with uPA:serpin complexes at 4°C, then
uPAR are expressed by the endogenous gene, while inacid-washed and further incubated at 37°C for various
murine LB6 clone 19 cells, ~5105 human receptors aretimes. The cells were then treated with PI-PLC for 15
expressed by the transfected SV40-driven cDNA (Stoppellimin at 37°C and released uPAR assayed by [125I]ATF
et al., 1985; Roldan et al., 1990). We nevertheless testedcross-linking, SDS–PAGE and autoradiography. Control,
the effect of the protein synthesis inhibitor cycloheximide,uPA-challenged, LB6 clone 19 cells displayed supernatant
in the temperature-dependent reversion to PI-PLC sensi-uPAR independently of the time of incubation at 37°C
tivity of LB6 clone 19 cells. The data showed that(Figure 7A). On the other hand, uPA:PN-1-treated cells
treatment of cells with cycloheximide (10 μg/ml, blockingshowed no uPAR in the PI-PLC supernatant before the
protein synthesis by 90% as shown by 35S metabolic37°C incubation (time zero); upon incubation at 37°C,
labelling of cells and TCA precipitation of lysates) addeduPAR reappeared, increasing linearly with time and reach-
30 min before incubation with uPA:PAI-1, had no influenceing a maximum at 60 min (Figure 7B). The finding that
PI-PLC resistance of uPAR in uPA:PN-1-incubated cells on the result (Figure 6B). Thus, recovery of PI-PLC
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Fig. 7. Incubation at 37°C reverses the PI-PLC resistance of uPAR in U937 and LB6 clone 19 cells challenged with uPA:PAI-1 or uPA:PN-1
complexes. (A) Acid-washed LB6 clone 19 cells were incubated on ice with 10 nM uPA for 90 min. Cells were warmed to 37°C for the indicated
times, transferred back to ice, acid-washed and treated with PI-PLC (5 U/ml) for 15 min at 37°C. Solubilized uPAR was assayed by cross-linking to
[125I]ATF, SDS–PAGE and autoradiography. Specificity was indicated by competition of [125I]ATF cross-linking with 100 nM unlabelled pro-uPA
(lanes marked ). (B) Conditions as in (A), except that the cells had been incubated with 10 nM uPA:PN-1. (C) Acid-washed U937 cells were
incubated on ice with 10 nM uPA (lanes 1–4) or 10 nM uPA:PAI-1 (lanes 5–8) for 60 min. Half of the cells were left on ice (lanes 1 and 2, and 5
and 6) and the other half warmed to 37°C for 120 min (lanes 3 and 4, and 7 and 8). All samples were acid-washed, treated with PI-PLC (3 U/ml)
for 15 min at 37°C, and supernatants cross-linked to [125I]ATF and analysed by SDS–PAGE and autoradiography. In lanes 1, 3, 5 and 7, excess
unlabelled pro-uPA was added for specificity control. (D) Acid-washed U937 cells were incubated with 10 nM uPA:PN-1 on ice for 90 min. Cells
were warmed to 37°C for the indicated times, transferred back to ice, acid-washed, treated with PI-PLC (5 U/ml) for 15 min at 37°C and the
supernatants assayed for the presence of solubilized uPAR as above. Specificity was indicated by competition of [125I]ATF binding to uPAR with
100 nM unlabelled pro-uPA (lanes marked ).
sensitivity did not depend on cell surface exposure of LRP and VLDL-R (Herz et al., 1992; Nykjær et al., 1992,
1994a; Heegaard et al., 1995). In the process, uPARnewly synthesized molecules.
That reversion to PI-PLC sensitivity could not be due itself is internalized through an α2MR-LRP-requiring
mechanism (Conese et al., 1995). When we analysed theto surface re-distribution of a previously intracellular
uPAR, was also shown by the absence of such a pool. internalization and degradation of uPA:PAI-1 through
uPAR immunofluorescence, we were surprised to find thatData in Figure 6A and B show that the lysates of LB6
clone 19 cells either not exposed to ligand or treated with the signal of internalized uPAR neither decreased nor
diminished with time (Figure 1), as would occur for thefree uPA did not contain any detectable uPAR after
treatment with PI-PLC, in agreement with the immuno- signal of the ligand (Olson et al., 1992). In fact, uPAR
was not degraded but was recycled back to the cell surface,fluorescence results of Figure 2. Indeed, uPAR was found
in the lysate before and in the supernatant after PI-PLC as shown by the following experiments. Immunocyto-
fluorimetry with uPA:serpin-incubated U937 cells showedtreatment. Finally, we have previously also shown efficient
cross-linking to [125I]ATF with intracellular uPAR (Møller that, at 37°C, the uPAR signal after an initial decrease
(due to the internalization) could be recovered at lateret al., 1992, 1993); therefore the failure to detect an
intracellular uPAR could not depend on a limitation of times (Figure 3). Similar results were obtained by immuno-
electron microscopy in EDTA-detached LB6 clone 19the assay.
cells (Figure 4). Finally, we surface-labelled uPAR with
biotin in LB6 clone 19 cells, incubated the cells at 37°CDiscussion
with uPA:PAI-1 to force uPAR internalization, and treated
cells with PI-PLC to eliminate non-internalized uPAR.Recycling
The ability to internalize and degrade uPA:serpin com- Upon further incubation at 37°C, biotinylated uPAR re-
appeared at the cell surface (Figure 5). Finally, theplexes is a unique property of uPAR in view of the absence
of a trans-membrane and cytosolic domain. This can only uPA:PAI-1 and uPA:PN-1-induced resistance of uPAR to
release by PI-PLC was reversed in time-dependent manneroccur because the uPAR-bound uPA:PAI-1 can interact
with proteins of the LDL-receptor family such as α2MR- on incubation at 37°C (Figures 6 and 7). All these data
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show that uPAR can recycle. The uPA:PAI-1 ligand, and an unidentified adaptor molecule (Wei et al., 1994,
1996; Bohuslav et al., 1995; Resnati et al., 1996).however, does not recycle (our unpublished data).
Recycling. While we have shown here the recycling of
Steps involved in uPA:PAI-1 clearance
uPAR, we have no information on the mechanism involved.From these and previous results, we can distinguish four
Also, while α2MR-LRP is known to be a recyclingsteps in the internalization of uPA:PAI-1: (i) binding of
receptor (Krieger and Herz, 1994), no information isuPA:PAI-1; (ii) induction of PI-PLC resistance of uPAR;
available on whether it recycles in the case of the(iii) endocytosis; and (iv) recycling. While binding of
uPA:PAI-1 internalization/degradation process. If so, theuPA:PAI-1 is essential to initiate the process, the other
recycling routes of the two receptors still need to betwo steps do not require its continuous presence.
defined.
Several unsolved problems persist therefore inBinding of uPA:PAI-1 to cell surface. In cells that contain
uPA:PAI-1 internalization. For example, the mechanismboth uPAR and α2MR-LRP, uPA:PAI-1 at low physio-
of dissociation of uPA:PAI-1 from uPAR and α2MR-LRP,logical concentrations will preferentially bind to uPAR
the endocytotic and recycling routes (preliminary databecause of its higher affinity (Cubellis et al., 1990; Nykjær
suggest that uPAR and α2MR-LRP can be observed withinet al., 1994a). Indeed, ATF and not RAP, competes for
the same endocytic vesicles; E.I.Christensen, unpublishedbinding of uPA:PAI-1 (Nykjær et al., 1992; Olson et al.,
observations), the molecular basis for the sorting of1992; Conese et al., 1994).
uPA:PAI-1 to lysosomes versus uPAR and α2MR-LRP to
PI-PLC resistance of uPAR. Indirect data point to the recycling, are issues that need to be addressed in the future.
formation of a quaternary complex between uPA:PAI-1,
uPAR and α2MR-LRP. Not only uPAR, but also α2MR-
Functional relevanceLRP antagonists prevent both degradation of uPA:PAI-1/
The ability of uPAR to recycle provides the plasminogenuPA:PN-1 (Nykjær et al., 1992; Conese et al., 1994) and
activation system with a novel property which is highlyuPAR internalization. Since the two moieties of uPA:PAI-1
relevant to its central function in the regulation of cellcan contact both uPAR and α2MR-LRP, respectively, a
migration. The aggressive, invasive phenotype of cancerquaternary complex might be formed in which the uPA:
cells is strongly tied to uPAR expression (Hearing et al.,PAI-1 complex bridges uPAR and α2MR-LRP. This step
1988; Ossowski, 1988; Crowley et al., 1993; Grøndahl-might occur also at 4°C. However, no direct demonstration
Hansen et al., 1995; Min et al., 1996) and the uPA/uPARof the formation of the quaternary complex has so far
system appears to be essential in cell recruitment inbeen made. Interestingly, uPAR becomes PI-PLC-resistant
inflammatory response (Bianchi et al., 1996; Gyetko et al.,already in the 4°C step, as shown by experiments such as
1996; Resnati et al., 1996). Several of the individualthose described in Figures 6 and 7 (not shown) in which
functions of uPAR have been shown to be involved inthe whole experiment was carried out at 4°C, including
the invasive behaviour of cancer: pro-uPA activation,PI-PLC release (90 min). The mechanism of PI-PLC
chemotaxis, cell adhesion, cell recruitment, etc. Moreover,resistance is not clear, but uPAR may either undergo a
PAI-1 itself inhibits cell adhesion and migration, throughconformational change or be shielded from PI-PLC by,
its ability to bind vitronectin and prevention of its inter-for example, α2MR-LRP.
action with integrins (Deng et al., 1996; Stefansson and
Lawrence, 1996; L.Kjøller, L.Ossowski and P.Andreasen,Internalization of the components of the quaternary
complex. When the temperature is raised to 37°C, the personal communication). On the other hand, vitronectin
itself is a ligand for uPAR and this provides an additionalinteraction of uPAR-bound uPA:PAI-1 with α2MR-LRP
triggers the internalization of the ligand and its degrada- adhesion mechanism for cells (Wei et al., 1994). Thus,
uPA/uPAR influence cell migration via both proteolytic,tion, as well as the internalization and recycling of uPAR.
However, at this point the presence of the ligand is no i.e. plasminogen activation (Cubellis et al., 1986; Stoppelli
et al., 1986; Ellis et al., 1989; Stephens et al., 1989),longer required for uPAR internalization (Figures 6 and
7). Thus, an initial step in which binding of the uPA:serpin and non-proteolytic mechanisms, i.e. by direct signalling
(adhesion and chemotaxis) (Busso et al., 1994; Resnaticomplex is essential to trigger the subsequent interaction
with α2MR-LRP is followed by the ligand-independent et al., 1996; Wei et al., 1996). PAI-1, on the other hand,
inhibits both proteolytic activity of uPA and the integrin-induction of PI-PLC resistance of uPAR and then by the
actual internalization. mediated cell adhesion and migration (Deng et al., 1996;
Stefansson and Lawrence, 1996; L.Kjøller, L.OssowskiHow is uPAR internalized in a α2MR-LRP-dependent
way if the ligand is no longer necessary at the time of the and P.Andreasen, personal communication). Thus, the
plasminogen activating system is strongly involved ininternalization? This might either occur through direct
contact between uPAR and α2MR-LRP, independently of the attachment/detachment machinery of cells, a process
obviously essential for cell migration. Indeed, uPA–/–the uPA:PAI-1 bridge, or through the intervention of other,
hitherto unknown and uncharacterized molecules. A direct homologous recombinant mice are deeply impaired in
inflammatory cell recruitment (Gyetko et al., 1996), andinteraction between uPAR and α2MR-LRP has no experi-
mental basis, but would not be surprising given the large the uPAR-binding domain of uPA blocks VEGF and
bFGF-induced angiogenesis (Min et al., 1996). In thissize of α2MR-LRP and the heterogeneity of its many
ligands (Krieger and Herz, 1994). The interaction of uPAR context, the ability of uPAR to induce internalization and
degradation of PAI-1 and to recycle back to the cellwith another protein is also plausible, since uPAR itself
has been reported to interact not only with uPA, but also surface appears to be a very important function in the
regulation of the attachment/detachment machinery. Thewith other molecules like vitronectin, integrins, caveolin
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1 mg/ml BSA) and treated with 5 U/ml PI-PLC at 37°C for 15 min oruPA/uPAR/PAI-1 system therefore appears to be able to
at 4°C for 90 min. On completion of incubation, the supernatants wereinform cells on when, how and where to move. It provides
recovered by centrifugation and assayed for solubilized uPAR by cross-
a ‘clear’ signal through plasminogen activation and uPAR linking to [125I]ATF and SDS–PAGE analysis (see below). In the case
occupancy, a ‘stop’ signal via PAI-1, and a ‘walk’ signal of LB6 clone 19 cells, 0.2106 cells were used, but methods and
conditions were otherwise identical. In some experiments, after PI-PLCthrough uPA:PAI-1 lysosomal degradation and the con-
treatment and collection of the supernatants, the pellets were lysed incomitant surface reappearance of naked uPAR.
lysis buffer (0.1 M Tris–HCl, pH 8.1, 10 mM EDTA, 1% Triton X-114
and 1% aprotinin) and cross-linked to [125I]ATF as described below.
Materials and methods
Cross-linking to [125I]ATF
Cell lysates or supernatants were cleared at 15 000 g for 10 min at 4°C
Materials
and tested for uPAR by cross-linking to [125I]ATF (50 000 c.p.m., 1500Two-chain uPA was obtained from Lepetit SpA (Milan, Italy), courtesy
c.p.m./fmol), using 1 mM DSS (disuccinimidyl suberate), as previouslyof Dr M.L.Nolli. ATF, the amino-terminal fragment of uPA (residues 1–
described (Picone et al., 1989). The samples were analysed by SDS–143) containing the receptor binding site (Stoppelli et al., 1985) was
PAGE (12% acrylamide) under non-reducing conditions (Laemmli,obtained from Abbott Laboratories (Chicago, IL), courtesy of Dr Jack
1970). The specificity of the ATF:uPAR conjugate was shown in allHenkin. Recombinant pro-uPA was obtained from Dr Paolo Sarmientos
cases by competition with 100 nM unlabelled two-chain uPA or pro-uPA.(Farmitalia, Italy). Anti-uPAR monoclonal antibodies R2, R3 and R4
(Rønne et al., 1991) were purified on a Protein G–Sepharose column
Immunodetection of surface-biotinylated uPARusing a commercial kit (mAbTrap™ G, Pharmacia LKB, Sweden) from
Biotinylation of cell surface proteins was carried out on 70–80%hybridoma cell culture supernatant received from Drs E.Rønne and
confluent LB6 clone 19 cells. After three washes with phosphate-bufferedG.Høyer-Hansen (Copenhagen, Denmark). Recombinant active PAI-1
saline (PBS), cells were incubated with 0.5 mg/ml sulfo-NHS-biotin for(Sherman et al., 1992) was a kind gift from Drs David Ginsburg (Ann
30 min at room temperature. The labelling solution was removed andArbor, MI) and Tor Ny (Umeå, Sweden); recombinant PN-1 (rPN-1)
the procedure repeated once. The cells were then washed three timeswas a generous gift of Dr Randy Scott (Incyte Co., CA). Preparation of
with PBS, treated with ligands and PI-PLC as described in the Resultsthe 39 kDa α2MR-LRP ligand RAP has been described previously
section and lysed. The lysate and the PI-PLC supernatant were supple-(Nykjær et al., 1992). GST and GST-RAP were kindly provided by Dr
mented with antibodies (monoclonals R2, R3 and R4 1 μg/ml each),J.Herz (Herz et al., 1991). Phosphatidylinositol-specific phospholipase
incubated for 1 h at 4°C with gentle rocking. Protein G–SepharoseC (PI-PLC) from Bacillus cereus was from Boehringer Mannheim
(50 μl of a 10% suspension) was added, the mixture further incubated(Germany). Benzamidine Sepharose 6B was from Pharmacia (Uppsala,
1 h at 4°C and centrifuged. The precipitate was washed, supplementedSweden); dimethyl-diphenylpolysiloxane and cycloheximide were from
with SDS-sample buffer, heated, centrifuged and the supernatant sub-Sigma Chemical Co. (St Louis, MO). The cross-linker disuccinimidyl-
jected to SDS–PAGE in 12.5% acrylamide. After transfer onto nitrocellu-suberate and sulfo-NHS-biotin were obtained from Pierce Chem Co.
lose filter (Schleicher & Schuell, Dassel, Germany), the blot was blocked(Rockford, IL).
in PBS–3% BSA for 1 h at room temperature. The membrane was then
washed six times with TBS–0.5% Tween 20 (TTBS) and incubated in
Cell-lines and cell cultures
PBS containing 0.5 mM CaCl2, 0.5 mM MgCl2, 1 M glucose, 10%Growth conditions for the human monocyte-like U937 and for the
(v/v) glycerol, 0.3% BSA and [125I]streptavidin (0.6 μCi/ml; Amersham)
murine LB6 clone 19 cells, a mouse cell line expressing the human
for 30 min at room temperature. After six washes in TTBS, the membrane
uPA-receptor, have been previously described (Picone et al., 1989;
was exposed to X-ray film at –80°C.
Roldan et al., 1990).
Mononuclear cells were obtained from the buffy coats of healthy
Light microscopic procedures
donors by Ficoll gradient sedimentation (Pharmacia, Uppsala, Sweden).
LB6 Clone 19 cells were studied either by conventional epifluorescence
Monocytes were separated by adhesion on plastic dishes (60 min at
or confocal microscopy: in both cases, the specimens were processed as
37°C, repeated once). T-lymphocytes were then isolated by panning on
described (Conese et al., 1995). Briefly, 0.2106 cells were plated onto
anti-CD16 antibodies to remove natural killer cells and passage through
24-well Costar plates containing 1.4 cm2 round glass coverslips. Cells
nylon wool fibres to remove B-lymphocytes. T-lymphocytes were stimu-
were fixed in 3% formaldehyde (from paraformaldehyde) in PBS
lated with 50 μg/ml PMA and 10 U/ml IL-2 for 48–72 h to induce the
pH 7.6–2% sucrose, for 10 min at 4°C to avoid permeabilization. For
synthesis of uPAR as previously described (Nykjær et al., 1994b).
permeabilization, coverslips were soaked, after fixation, for 3–5 min in
HEPES–Triton X-100 buffer (20 mM HEPES, pH 7.4, 3 mM MgCl2
Iodinations and 0.5% Triton X-100). Primary monoclonal anti-uPAR antibody R2
Iodination of ATF or uPA with Iodogen (Pierce Chemical Co.) has been was used at 15 μg/ml in TBS–0.2% bovine serum albumin; a fluorescein-
described (Behrendt et al., 1990). Specific activities of the proteins tagged secondary antibody (Protos Immunoresearch, San Francisco, CA)
ranged between 2.5105 and 4.0106 c.p.m./pmol. Iodinated uPA was used at a 1:200 dilution in TBS–0.2% bovine serum albumin.
retaining enzymatic activity was purified by affinity chromatography on Conventional epifluorescence was carried out on a Zeiss Axiophot
benzamidine–Sepharose 6B (Holmberg et al., 1976). microscope and photomicrographs were recorded on a Kodak T-MAX
400 film exposed at 1000 ISO (Eastman Kodak, Rochester, NY). For
Formation of uPA:serpin complexes confocal microscopy, a Sarastro 2000 confocal laser scanning system
Labelled uPA:PAI-1 complexes were formed combining benzamidine– (Molecular Dynamics, Sunnyvale, CA) attached to a Zeiss Axioskop
Sepharose-purified 125I-labelled or unlabelled uPA and a 20-fold molar fluorescence microscope was employed. The objectives used were a
excess of PAI-1 at room temperature for 1 h. The inhibitor:uPA ratio plan-apochromatic 631.4 and a plan-apochromatic 1001.3 (Carl
was experimentally determined to convert 90% of the uPA to the Zeiss). Optical sections of 0.29 μm thickness were saved as 512512
complex form as determined by SDS–PAGE analysis (not shown). pixel images and then processed on a McIntosh computer. Final images
Similarly, uPA:rPN-1 was formed at a 1:50 ratio as previously described were printed on photographic quality paper with a Kodak DL-7700
(Conese et al., 1994). Purified, preformed uPA:PAI-1 complex for sublimation ink printer.
immunoelectron microscopy experiments was a kind gift of Dr Peter
A.Andreasen and was prepared as described before (Nykjær et al., 1994a). Cytofluorimetric analysis
Acid-washed-U937 cells (1106) were incubated with uPA:PAI-1 or
Release of surface-bound ligand uPA:PN-1 complexes for 2 h at 4°C and then transferred at 37°C for
Surface-bound ligands were detached from the plasma membrane either different times. Cells were then washed twice with PBS, and incubated
by dissociation with acid-washing (Stoppelli et al., 1986) or by incubating in 0.1 ml PBS and 25 μg/ml of anti-uPAR monoclonal antibody R2.
cells with 5 U/ml PI-PLC (Ploug et al., 1991) at 37°C for 15 min. After 30 min of incubation at 4°C, cells were washed twice with PBS
and resuspended in PBS containing a 1:50 dilution of fluorescein-
conjugated antibody against mouse IgG (Dakopatts, Copenhagen,PI-PLC sensitivity of uPAR
Approximately 2106 U937 cells (previously incubated under conditions Denmark). After 30 min at 4°C, cells were washed twice and analysed
by flow cytofluorimetry with a FACScan apparatus (Becton-Dickinson,indicated in the individual experiments) were resuspended in 0.1 ml
binding buffer (RPMI-1640 containing 50 mM HEPES, pH 7.4 and San Jose, CA). To express the data, the cell number was plotted against
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the log of the mean fluorescence intensity, with ~5000 cells being Bartke,I., Knapp,W. and Stockinger,H. (1995) Urokinase plasminogen
measured at each determination. The negative control was obtained activator receptor, beta-2 integrins and Src-kinases within a single
incubating the cells in the absence of the primary antibody. receptor complex of human monocytes. J. Exp. Med., 181, 1381–1390.
Busso,N., Masur,S.K., Lazega,D., Waxman,S. and Ossowski,L. (1994)
Electron microscopy Induction of cell migration by pro-urokinase binding to its receptor:
LB6 clone 19 cells (5106) were pretreated for 30 min with 10 μg/ml possible mechanism for signal transduction in human epithelial cells.
cycloheximide and incubated (protocol a) for 2 h with 100 nM uPA:PAI- J. Cell Biol., 126, 259–270.
1 at 0°C, washed, treated with 5 U/ml PI-PLC at 37°C for 15 min and Conese,M., Olson,D. and Blasi,F. (1994) Protease nexin-1-urokinase
then fixed. To demonstrate possible recycling (protocol b), cells were complexes are internalized and degraded through a mechanism that
washed after the incubation step with PI-PLC, further incubated for requires both urokinase receptor and α2-macroglobulin receptor.
120 min in the presence of cycloheximide at 37°C, and then fixed J. Biol. Chem., 269, 17886–17892.
following detachment from coverslips with EDTA. The cells were fixed Conese,M., Nykjær,A., Petersen,C.M., Cremona,O., Pardi,R.,
with 0.1% glutaraldehyde and 2% formaldehyde in 0.1 M sodium Andreasen,P.A., Gliemann,J., Christensen,E.I. and Blasi,F. (1995) α2-
cacodylate buffer, pH 7.2, for 1 h and subsequently post-fixed for up to macroglobulin receptor/LDL receptor-related protein (LRP)-dependent
18 h in 2% formaldehyde in the same buffer. The cells were embedded internalization of the urokinase receptor. J. Cell Biol., 131, 1609–1622.
in 15% gelatin, then infiltrated with 2.3 M sucrose containing 2% Crowley,C.W., Cohen,R.L., Lucas,B.K., Liu,G., Shuman,M.A. and
formaldehyde for 30 min and frozen in liquid nitrogen. Ultrathin Levinson,A.D. (1993) Prevention of metastasis by inhibition of the
cryosections, 70–90 nm, were obtained with a RCS Reichert Ultracut S urokinase receptor. Proc. Natl Acad. Sci. USA, 90, 5021–5025.
cryoultramicrotome at approximately –100°C and collected on 300 Mesh Cubellis,M.V., Nolli,M.L., Cassani,G. and Blasi,F. (1986) Binding of
Ni grids. The sections were incubated overnight at 4°C with polyclonal single-chain pro-urokinase to the urokinase receptors on human U937
affinity-purified rabbit anti-uPAR IgG (5 μg/ml) and subsequently with cells. J. Biol. Chem., 261, 15819–15822.
10 nm goat anti-rabbit-gold (BioCell, Cardiff, UK) at 4°C for 2 h. The Cubellis,M.V., Wun,T.-C. and Blasi,F. (1990) Receptor-mediated
sections were finally contrasted with methyl cellulose containing 0.3% internalization and degradation of urokinase is caused by its specific
uranyl acetate (Tokuyasu, 1978; Griffiths et al., 1984) and studied in a inhibitor PAI-1. EMBO J., 9, 1079–1085.
Philips EM208 or Philips CM100 electron microscope. Danø,K., Behrendt,N., Brunner,N., Ellis,V., Plough,M. and Pyke,C.
Immunogold distribution over the cells was determined as follows: (1994) The urokinase receptor: protein structure and role in
~25 electron micrographs were taken at random but including as much plasminogen activation and cancer invasion. Fibrinolysis, 8 (Suppl.
cytoplasm and cell surface as possible from each of the two groups (a 1), 189–203.
and b) at a primary magnification of 11 500 and then enlarged 3-fold. Deng,G., Curriden,S.A., Wang,S., Rosenberg,S. and Loskutoff,D.J.
Gold particles were counted over the plasma membrane, over cytoplasmic (1996) Is plasminogen activator inhibitor-1 the molecular switch that
vacuoles, and over the nucleus. The cytoplasmic areas analysed in the governs urokinase-receptor-mediated cell adhesion and release? J. Cell
two groups as determined by point-counting were essentially identical: Biol., 134, 1563–1571.
(a) 1210 μm2 and (b) 1215 μm2. The total number of gold particles Ellis,V., Behrendt,N. and Danø,K. (1991) Plasminogen activation by
counted was 5298. The background labelling which was determined by receptor-bound urokinase: A kinetic study with both cell-associated
the number of particles present over the nucleus was 0.16/μm2 in and isolated receptor. J. Biol. Chem., 266, 12752–12758.
protocol a and 0.10/μm2 in protocol b. Estreicher,A., Mulhauser,J., Carpentier,J.-L., Orci,L. and Vassalli,J.-D.
(1990) The receptor for urokinase type plasminogen activator polarizes
expression of the protease to the leading edge of migrating monocytesAcknowledgements
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